Rituximab postprogressive multifocal leukoencephalopathy: a Feasible therapeutic option in selected cases

Today, a growing armamentarium of potent immunotherapies exists for the treatment of severe relapsing remitting multiple sclerosis (RRMS). Some of these drugs may cause progressive multifocal leukoencephalopathy (PML), a John Cunningham virus (JCV) infection of the central nervous system [Dahlhaus et al. 2013; Hoepner et al. 2014; Schmedt et al. 2012]. In PML survivors, RRMS-disease activity will usually return to high pre-natalizumab (Nat)...